Cocaine

CAS# 50-36-2

Cocaine

Catalog No. BCN1901----Order now to get a substantial discount!

Product Name & Size Price Stock
Cocaine: 5mg Please Inquire In Stock
Cocaine: 10mg Please Inquire In Stock
Cocaine: 20mg Please Inquire Please Inquire
Cocaine: 50mg Please Inquire Please Inquire
Cocaine: 100mg Please Inquire Please Inquire
Cocaine: 200mg Please Inquire Please Inquire
Cocaine: 500mg Please Inquire Please Inquire
Cocaine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Cocaine

Number of papers citing our products

Chemical structure

Cocaine

3D structure

Chemical Properties of Cocaine

Cas No. 50-36-2 SDF Download SDF
PubChem ID 446220 Appearance Powder
Formula C17H21NO4 M.Wt 303.35
Type of Compound Alkaloids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name methyl (1S,3S,4R,5R)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate
SMILES CN1C2CCC1C(C(C2)OC(=O)C3=CC=CC=C3)C(=O)OC
Standard InChIKey ZPUCINDJVBIVPJ-LJISPDSOSA-N
Standard InChI InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Cocaine

Description1. Cocaine is a powerfully addictive stimulant drug made from the leaves of the coca plant native to South America, it produces short-term euphoria. 2. Cocaine constricts blood vessels, dilates pupils, and increases body temperature, heart rate, and blood pressure. 3. Cocaine has a small number of accepted medical uses such as numbing and decreasing bleeding during nasal surgery. 4. Cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A, thus providing a mechanism by which stress induces Cocaine seeking. 5. Cocaine can cause headaches and gastrointestinal complications such as abdominal pain and nausea. Because cocaine tends to decrease appetite, chronic users can become malnourished as well.
TargetsNMDAR | HIV | gp120/CD4

Cocaine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Cocaine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Cocaine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.2965 mL 16.4826 mL 32.9652 mL 65.9304 mL 82.4131 mL
5 mM 0.6593 mL 3.2965 mL 6.593 mL 13.1861 mL 16.4826 mL
10 mM 0.3297 mL 1.6483 mL 3.2965 mL 6.593 mL 8.2413 mL
50 mM 0.0659 mL 0.3297 mL 0.6593 mL 1.3186 mL 1.6483 mL
100 mM 0.033 mL 0.1648 mL 0.3297 mL 0.6593 mL 0.8241 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Cocaine

Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse.[Pubmed:25788713]

J Pharmacol Exp Ther. 2015 Jun;353(3):465-70.

Schizophrenia is associated with high prevalence of substance abuse. Recent research suggests that dysregulation of N-methyl-d-aspartate receptor (NMDAR) function may play a role in the pathophysiology of both schizophrenia and drug addiction, and thus, may account for this high comorbidity. Our laboratory has developed two transgenic mouse lines that exhibit contrasting NMDAR activity based on the availability of the glycine modulatory site (GMS) agonists d-serine and glycine. Glycine transporter 1 knockdowns (GlyT1(+/-)) exhibit NMDAR hyperfunction, whereas serine racemase knockouts (SR(-/-)) exhibit NMDAR hypofunction. We characterized the behavior of these lines in a Cocaine-induced (20 mg/kg) conditioned place preference (CPP) and locomotor sensitization paradigm. Compared with wild-type mice, GlyT1(+/-) mice displayed hastened extinction of CPP and robust Cocaine-induced reinstatement. SR(-/-) mice appeared to immediately "forget" the learned preference, because they did not exhibit Cocaine-induced reinstatement and also displayed attenuated locomotor sensitization. Treatment of GlyT1(+/-) mice with gavestinel (10 mg/kg on day 1; 5 mg/kg on days 2-17), a GMS antagonist, attenuated Cocaine-induced CPP and caused them to immediately "forget" the learned preference. Treatment of SR(-/-) mice with d-serine (300 mg/kg on day 1; 150 mg/kg on days 2-17) to normalize brain levels caused them to avoid the Cocaine-paired side of the chamber during extinction. These results highlight NMDAR dysfunction as a possible neural mechanism underlying comorbid schizophrenia and substance abuse. Also, these findings suggest drugs that directly or indirectly activate the NMDAR GMS could be an effective treatment of Cocaine abuse.

Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.[Pubmed:25926444]

J Neurosci. 2015 Apr 29;35(17):6639-53.

Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegmental area (VTA) play an important role in stress-induced Cocaine-seeking behavior. We provide evidence for pharmacologically significant interactions between CRF and orexin-A that depend on oligomerization of CRF1 receptor (CRF1R) and orexin OX1 receptors (OX1R). CRF1R-OX1R heteromers are the conduits of a negative crosstalk between orexin-A and CRF as demonstrated in transfected cells and rat VTA, in which they significantly modulate dendritic dopamine release. The Cocaine target sigma1 receptor (sigma1R) also associates with the CRF1R-OX1R heteromer. Cocaine binding to the sigma1R-CRF1R-OX1R complex promotes a long-term disruption of the orexin-A-CRF negative crosstalk. Through this mechanism, Cocaine sensitizes VTA cells to the excitatory effects of both CRF and orexin-A, thus providing a mechanism by which stress induces Cocaine seeking.

Cocaine modulates HIV-1 integration in primary CD4+ T cells: implications in HIV-1 pathogenesis in drug-abusing patients.[Pubmed:25691383]

J Leukoc Biol. 2015 Apr;97(4):779-90.

Epidemiologic studies suggest that Cocaine abuse worsens HIV-1 disease progression. Increased viral load has been suggested to play a key role for the accelerated HIV disease among Cocaine-abusing patients. The goal of this study was to investigate whether Cocaine enhances proviral DNA integration as a mechanism to increase viral load. We infected CD4(+) T cells that are the primary targets of HIV-1 in vivo and treated the cells with physiologically relevant concentrations of Cocaine (1 microM-100 microM). Proviral DNA integration in the host genome was measured by nested qPCR. Our results illustrated that Cocaine from 1 microM through 50 microM increased HIV-1 integration in CD4(+) T cells in a dose-dependent manner. As integration can be modulated by several early postentry steps of HIV-1 infection, we examined the direct effects of Cocaine on viral integration by in vitro integration assays by use of HIV-1 PICs. Our data illustrated that Cocaine directly increases viral DNA integration. Furthermore, our MS analysis showed that Cocaine is able to enter CD4(+) T cells and localize to the nucleus-. In summary, our data provide strong evidence that Cocaine can increase HIV-1 integration in CD4(+) T cells. Therefore, we hypothesize that increased HIV-1 integration is a novel mechanism by which Cocaine enhances viral load and worsens disease progression in drug-abusing HIV-1 patients.

Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients.[Pubmed:25592977]

Psychiatry Res. 2015 Feb 28;225(3):309-14.

Brain-derived neurotrophic factor (BDNF) is involved in Cocaine craving in humans and drug seeking in rodents. Based on this, the aim of this study was to explore the possible role of serum BDNF in Cocaine relapse in abstinent addicts. Forty Cocaine dependent subjects (DSM-IV criteria) were included in an inpatient 2 weeks abstinence program. Organic and psychiatric co-morbidities were excluded. Two serum samples were collected for each subject at baseline and at after 14 abstinence days. After discharge, all Cocaine addicts underwent a 22 weeks follow-up, after which they were classified into early relapsers (ER) (resumed during the first 14 days after discharge,) or late relapsers (LR) (resumed beyond 14 days after discharge). The only clinical differences between groups were the number of consumption days during the last month before detoxification. Serum BDNF levels increased significantly across the 12 days of abstinence in the LR group (p=0.02), whereas in the ER group BDNF remained unchanged. In the ER group, the change of serum BDNF during abstinence negatively correlated with the improvement in depressive symptoms (p=0.02). These results suggest that BDNF has a role in relapse to Cocaine consumption in abstinent addicts, although the underlying neurobiological mechanisms remain to be clarified.

Effects of cocaine-positive urine screens on serum thyrotropin levels in patients admitted to an inpatient mental health unit.[Pubmed:25688900]

South Med J. 2015 Feb;108(2):130-1.

OBJECTIVE: To assess the effect of a positive urine screen for Cocaine on thyrotropin (TSH, also thyroid-stimulating hormone) concentrations. METHODS: In this retrospective cohort study, patients admitted to the mental health unit at an academic inpatient setting with a diagnosis of Cocaine dependence or Cocaine intoxication were routinely screened with urine drug toxicology tests and TSH concentrations. TSH concentrations from patients who tested positive for Cocaine on urine toxicology were compared with patients having negative Cocaine screenings. RESULTS: A total of 192 patients were included: 122 with a positive Cocaine screen and 70 with a negative Cocaine screen. All patients were screened using a highly sensitive TSH assay. A positive Cocaine screen was not associated with a statistically significant difference in TSH concentrations compared with a negative Cocaine screen. The percentage of patients with hypothyroidism (TSH >4.50 muIU/mL) or hyperthyroidism (TSH <0.40 muIU/mL) were similar in both study groups. CONCLUSIONS: The study failed to show that a positive urine screen for Cocaine was associated with a significant effect on serum TSH levels in patients admitted to a mental health unit with a diagnosis of Cocaine dependence or Cocaine intoxication. Our findings support those of a prior study that Cocaine use does not affect routine thyroid function tests. The present study does not support the clinical practice of ordering a serum TSH screening test on patients admitted to inpatient psychiatry units soley because the urine screen is positive for Cocaine.

Keywords:

Cocaine,50-36-2,Natural Products, buy Cocaine , Cocaine supplier , purchase Cocaine , Cocaine cost , Cocaine manufacturer , order Cocaine , high purity Cocaine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: